HomeVideoMonika Konaklieva | American University | USA | Europharma 2016 | Conference Series LLC

Monika Konaklieva | American University | USA | Europharma 2016 | Conference Series LLC



European Pharm Congress August 25-27, 2015 Valencia, Spain

Scientific Talk On: b-Lactams cidal against Mycobacterium tuberculosis
Click here for Abstract and Biography: http://europe.pharmaceuticalconferences.com/abstract/2015/b-lactams-cidal-against-mycobacterium-tuberculosis

Conference Series LLC (3000+ Global Events): conferenceseries.com 
Global Medical Conferences: conferenceseries.com
Global Nursing Conferences: nursingconference.com
Global Pharmaceutical Conferences: pharmaceuticalconferences.com
Global Cancer Conferences: cancersummit.org 
Global Diabetes Conferences: diabetesexpo.com 
Global Dental Conferences: dentalcongress.com 
700+ Open Access Journals: omicsonline.org 

Biography:

Monika Konaklieva is an organic synthetic/medicinal chemist, whose research focuses on the synthesis and evaluation of new antibacterial, neuroprotective and anticancer agents, as well as development of efficient and environmentally friendly synthetic approaches for their preparation. She obtained her doctoral degree in Organic Synthetic Chemistry from State University of New York at Buffalo (1997). She was a visiting Assistant Professor at the School of Pharmacy, Midwestern University, Chicago, IL (1997-1999). She is currently an Associate Professor in the Department of Chemistry, Washington, DC. In 2007, she spent her sabbatical leave at the Tuberculosis Research Section, LCID, NIAID, NIH

Abstract:

We have designed, synthesized, and tested monocyclic β-lactams that carry thiophenoxy group at C4. These thioethers have shown good intrinsic activity against serine β-lactamase producing Mycobacterium tuberculosis H37Rv (Mtb). Some of the compounds have demonstrated minimal inhibitory concentration (MIC) as low as 6.25 g/ml in 7H9 and 1.5 g/ml in GAST. Our investigations indicate that these compounds are cidal to both replicating and non-replicating persistent Mtb. These compounds have also shown activity against multi-drug resistant strains of M. tuberculosis. Therefore, they are promising candidates for lead discovery. Mechanism of action and target identification studies which are currently underway

Likes: 0

Viewed:

source

Previous post
Type-2 Diabetes Prevention and control : Kannada
Next post
DIABETES PSA FCV 8TH GRADE BIOLOGY

Leave a Reply

Be the First to Comment!

Notify of
avatar
wpDiscuz